BioLexis is a biotechnology company that specializes in the development of innovative therapeutics and diagnostics. The company leverages cutting-edge research and development to address complex health challenges, focusing on areas with significant unmet medical needs.

BioLexis

Moleculern™ – The Next Evolution in Drug DiscoveryScreening each Moleculern™ fragment against a curated protein target library has resulted in 600K real/empirical data points and scaffold-like compounds that can be used to design new drug candidates and to accelerate the discovery process. Our empirically rich Moleculern™ technology is rapidly creating, discovering, and developing novel pre-clinical to clinical stage agents. Our modern chemical biology approach coupled with our advanced machine learning and AI-backed platform accelerates discoveries by mapping hot-spots, computing ligand properties and building accurate empirical models which translate into active, safe, and efficacious novel chemical entities (NCEs) of future medicines.Biolexis is developing better and safer drugs faster through Moleculern™:    Accelerates drug discovery/development to new therapeutics     Shortens the path to the clinic to increase the probability of success    Expedites to First-In-Human (FIH) clinical trials    Facilitates delivery of medicines to patients worldwide

COM:BIOLEXISTX

BioLexis

Financials Not Available